Ata Abbasi1, Negar Faramarzi2, Mohsen Khosravi3,4, Fatemeh Yazarloo5, Mohammad Amin Abbasi6, Ahmad R Dehpour3,4, Issa Jahanzad7. 1. Department of Pathology, Urmia University of Medical sciences (UMSU), Urmia, Iran. 2. Department of Medicine, Brigham and Women's Hospital, Biomaterials Innovation Research Center, Harvard Medical School, Cambridge, MA 02139, USA. 3. Department of Pharmacology, Tehran University of Medical Sciences, Tehran, Iran. 4. Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran. 5. Department of Medical Genetics, Tehran University of Medical Sciences, Tehran, Iran. 6. Department of Internal Medicine, Shahid Beheshti Medical University, Tehran, Iran. 7. Department of Pathology, Tehran University of Medical sciences (TUMS), Tehran, Iran.
Abstract
BACKGROUND: Cirrhosis, a common consequence of chronic liver inflammation is associated with various cardiovascular dysfunctions which are called cirrhotic cardiomyopathy (CC). Among the various possible causes of CC, apoptosis is considered to have a pivotal role. OBJECTIVES: To explore the contribution of endogenous opioids in the apoptosis process in a rat model of CC. MATERIAL AND METHODS: Four genes were selected to cover both intrinsic and extrinsic pathways of apoptosis. Cardiac samples from 4 groups of rats were evaluated. Two groups were cirrhotic through bile duct ligation (BDL) receiving either naltrexone (BDL-naltrexone) or saline (BDL-saline), two others were normal rats as sham groups receiving either naltrexone (sham-naltrexone) or saline (sham-saline). Expression level of BCL2, Caspase3, Fas and FasL was explored in all groups using reverse transcriptase real-time PCR. RESULTS: BDL-saline group showed significant over-expression of BCL2, caspase3 and Fas. BCL2 expression was 1.44 (P < 0.001) and caspasse3 was 1.35 (P < 0.001) times higher than sham-saline group, Fas was also overexpressed 1.3 (P < 0.001) times higher than BDL-naltrexone group and 1.91 (P < 0.001) compared to sham-naltrexone group. Caspase3 expression was 1.35 (P < 0.001) folds higher than sham-naltrexone group. The expression pattern of FasL revealed no statistically significant change among study groups. CONCLUSION: Fas molecule enrollment during CC is a novel finding. Fas molecule is activated during cirrhosis through elevated levels of endogenous opioids. This pathway is one of the leading causes of CC. Our findings also demonstrated the protective role of naltrexone as opioids antagonist on cardiomyocytes in a rat model of CC.
BACKGROUND:Cirrhosis, a common consequence of chronic liver inflammation is associated with various cardiovascular dysfunctions which are called cirrhotic cardiomyopathy (CC). Among the various possible causes of CC, apoptosis is considered to have a pivotal role. OBJECTIVES: To explore the contribution of endogenous opioids in the apoptosis process in a rat model of CC. MATERIAL AND METHODS: Four genes were selected to cover both intrinsic and extrinsic pathways of apoptosis. Cardiac samples from 4 groups of rats were evaluated. Two groups were cirrhotic through bile duct ligation (BDL) receiving either naltrexone (BDL-naltrexone) or saline (BDL-saline), two others were normal rats as sham groups receiving either naltrexone (sham-naltrexone) or saline (sham-saline). Expression level of BCL2, Caspase3, Fas and FasL was explored in all groups using reverse transcriptase real-time PCR. RESULTS:BDL-saline group showed significant over-expression of BCL2, caspase3 and Fas. BCL2 expression was 1.44 (P < 0.001) and caspasse3 was 1.35 (P < 0.001) times higher than sham-saline group, Fas was also overexpressed 1.3 (P < 0.001) times higher than BDL-naltrexone group and 1.91 (P < 0.001) compared to sham-naltrexone group. Caspase3 expression was 1.35 (P < 0.001) folds higher than sham-naltrexone group. The expression pattern of FasL revealed no statistically significant change among study groups. CONCLUSION:Fas molecule enrollment during CC is a novel finding. Fas molecule is activated during cirrhosis through elevated levels of endogenous opioids. This pathway is one of the leading causes of CC. Our findings also demonstrated the protective role of naltrexone as opioids antagonist on cardiomyocytes in a rat model of CC.
Entities:
Keywords:
BDL, bile duct ligation; CC, cirrhotic cardiomyopathy; Fas; H&E, Hematoxylin and Eosin; MAPKs, mitogen-activated protein kinases; NO, nitric oxide; apoptosis; cirrhotic cardiomyopathy; opioid; qRT-PCR, Real-Time Reverse Transcription PCR
Authors: Enrico M Zardi; Antonio Abbate; Domenico Maria Zardi; Aldo Dobrina; Domenico Margiotta; Benjamin W Van Tassell; Benjamin W Van Tassel; Antonella Afeltra; Arun J Sanyal Journal: J Am Coll Cardiol Date: 2010-08-10 Impact factor: 24.094
Authors: Ana M Tormos; Alessandro Arduini; Raquel Talens-Visconti; Ivan del Barco Barrantes; Angel R Nebreda; Juan Sastre Journal: Hepatology Date: 2013-01-25 Impact factor: 17.425
Authors: John G Walsh; Sean P Cullen; Clare Sheridan; Alexander U Lüthi; Christopher Gerner; Seamus J Martin Journal: Proc Natl Acad Sci U S A Date: 2008-08-22 Impact factor: 11.205
Authors: Ata Abbasi; Adel Joharimoqaddam; Negar Faramarzi; Mohsen Khosravi; Issa Jahanzad; Ahmad R Dehpour Journal: Ann Med Health Sci Res Date: 2014-05